Summit Therapeutics (MEX:SMMT) Change In Receivables: MXN0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Change In Receivables?

Summit Therapeutics MEX:SMMT 30 Change In Receivables is MXN0.00 Mil as of Jun. 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Summit Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was MXN0.00 Mil. It means Summit Therapeutics's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Summit Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was MXN0.00 Mil. It means Summit Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Summit Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was MXN0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Summit Therapeutics's liquidation value for the three months ended in Jun. 2026 was MXN9,919.34 Mil.

Summit Therapeutics  (MEX:SMMT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Summit Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Summit Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Summit Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=12051.64-2132.303+0.75 * 0+0.5 * 0
=9,919.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Change In Receivables Related Terms

Summit Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Change In Receivables Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -146.74 183.50 76.84 11.16 0.00

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of MXN0.00 Mil mean?
Summit Therapeutics (MEX:SMMT) has a Change In Receivables of MXN0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Summit Therapeutics and its competitors.
Is Summit Therapeutics' Change In Receivables too high?
Summit Therapeutics' current Change In Receivables is MXN0.00 Mil. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Change In Receivables compare to TECH and AXSM?
Summit Therapeutics' Change In Receivables of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Summit Therapeutics and its competitors. Summit Therapeutics's current Change In Receivables is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Change In Receivables of MXN0.00 Mil. The current Change In Receivables is MXN0.00 Mil. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Change In Receivables is MXN0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price